Actively Recruiting
Prospective Multicenter Study on Digestive Tract Cancer Screening Using Combined Blood Multi-Gene Methylation and Fecal Biomarkers
Led by Xijing Hospital · Updated on 2026-08-18
5000
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new screening method combining blood multi-gene methylation and fecal biomarkers to detect cancers throughout the digestive tract early. This observational study focuses on individuals aged 45 to 74 who are scheduled for digestive tract endoscopy. The goal is to establish a novel system that improves early diagnosis by measuring the sensitivity and specificity of these combined biomarkers. Participants will provide blood and stool samples before undergoing the endoscopic examination. The samples will be tested for specific gene methylation and fecal markers such as the immunochemical test and calprotectin. After the initial screening and endoscopic procedures with pathological confirmation, participants will be followed for five years to monitor outcomes and validate the screening method. Throughout the study, researchers will collect data on the accuracy of the combined biomarkers compared to endoscopy results, as well as track the detection rates of precancerous lesions and various digestive tract cancers over time. The study will also monitor any complications related to endoscopic screening, such as bleeding or infection. Participants will be involved in baseline sample collection, endoscopy, and long-term follow-up visits over five years.
CONDITIONS
Brief Title
A Multicenter Prospective Observational Cohort Study for Digestive Tract Tumor Screening Using Multi-Target Blood and Fecal Biomarkers
Research Team
R
Rong Zheng
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here